Objective: To detect the prevalence of sexual dysfunction and also to investigate possible risk factors that may cause sexual dysfunction in the Indian women.
INTRODUCTION
The sexual response in women is expressed by different phases (desire, arousal, lubrication, plateau, orgasm and resolution). The first three components are interdependent. Healthy sexual functioning is an important contributor to women's sense of well-being and quality of life. The presence of more than one dysfunction should be ascertained, because considerable interdependence may exist. Long-term medical diseases, minor ailments, medications and psychosocial difficulties, including prior physical or sexual abuse, are etiologic factors. Gynecologic maladies and cancers (including breast cancer) are also frequent sources of sexual dysfunction, which in turn results in distress and agony. Evaluation of psychological and pathophysiological factors responsible for female sexual dysfunction can be easily dealt with psychogenic treatment based on cognitive behavioral and psychodynamic approaches, drug therapy or surgery.
MATERIALS AND METHODS
Total of 500 patients were studied in the Outpatient Clinic of Department of Obstetrics and Gynecology in our Institute at Ahmedabad. Oral informed consent regarding study was taken. Women not living with their husbands in the past 6 months were excluded. Female sexual function index Proforma in three languages (Hindi, English and Gujarati) that had been previously pilot tested for cultural appropriateness and linguistic accuracy was given to consenting participants and illiterate women were interviewed personally. Patients with past history any psychiatric illness, endocrinological disorder or on antihypertensive drugs were excluded from the study.
Female Sexual Functioning Index
Female sexual functioning index (FSFI) is a brief, multidimensional scale for assessing sexual function in women. Higher score indicates better sexual function. The questionnaire consists of 19 questions covering 6 domains-desire (2 questions), arousal, lubrication (4 questions-each), orgasm, satisfaction, pain (3 questions each). Response to each question relates to previous month and are scored either from 0 (no sexual activity), 1 (indicative of dysfunction) to 5 (suggestive of normal sexual activity). Individual domain scores are obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor provided in the FSFI for each domain. The full scale score is obtained by adding the 6 domain score. The minimal score possible is 2 and the maximum is 36. The cutoff score to demarcate sexual dysfunction is 26.55, as obtained from a validation study. Accordingly scores less than 4.28, 5.08, 5.45, 5.05, 5.04 and 5.51 on the desire, arousal and lubrication. Orgasm, satisfaction and pain domains respectively were used to classify participants with such dysfunction reliably.
Statistical Analysis
All statistical analysis was performed using the statistical package for the social sciences (SPSS version 12.0). Continuous variables were compared using Student t-test. Chi-square test of Fisher exact test were used to assess the effect of change in differences in categorical variables. Data values are expressed as mean ± SD, count (%age) and p < 0.05 is considered to be statistically significant.
OBSERVATION AND RESULTS
Out of 500 patients 278 (55.6%) patients were suffering from FSD with mean FSFI score 17.8 ± 5.92 which is statistically significant (p < 0.0001) ( Table 1 ). In patients suffering from FSD, 91.7% of patients had orgasmic dysfunction followed by lubrication in 89.2% of patients , dyspareunia in 86.6%, arousal in 80.5% and satisfaction disorders in 79.4% of patients. Desire was the least common sexual dysfunction encountered in (48.2% of patients) ( Table 2) . Table 3 depicts that, in the age group of 24 to 30 years, 99 (44.5%) patients had no FSD and 83 (29.8%) patients suffered from FSD (p-value, 0.0006). In the age group of >42 years of total population, 36 (12.9%) patients had FSD as compared to only 6 (2.7%) patients with no FSD (p-value, 0.00004). It clearly indicates that FSD increases as the age advances and prevalence of FSD is lesser in younger age group.
In the 38 to 42 years age group, the most common disorder was orgasmic dysfunction followed by arousal and desire disorder with p-values 0.006, 0.00003 and 0.020 respectively ( Table 4 ). In females of more than 42 years age, the commonest disorder was arousal dysfunction followed by satisfaction with p-values 0.003 and 0.001 respectively (Table 4 ). Regarding education status , 7.19% illiterate patients had FSD as compared to only 3.15% illiterate patients with no FSD (p = 0.047) ( Table 5 ). Endometriosis and PID are the associated risk factors with female sexual dysfunction ( Table 5) .
A comprehensive literature review by Simons and Carey 1 notes an overall prevalence of desire 5 to 46%, arousal 7 to 10% and orgasmic disorders 7 to 10%. Shokrollahoi 2 et al in Iran revealed prevalence of desire 15%, orgasm 26%, lubrication 15%, vaginismus 8% and dyspareunia 10%. Thirtyeight percent of women had at least one sexual dysfunction. Alaleh Asghari Roodsari 3 et al found prevalence of desire, orgasm, pain and lubrication as 20, 36.7, 6.7 and 33.3%. Cayan 4 et al depicted the prevalence of FSD 21.7% in the age group of 18 to 27 years, 25.5% in 28 to 37 years, 53.5% in 38 to 47 years, 65.9% in 48 to 57 years and 92.9% in 58 to 67 years. Singh JC et al 5 in 2009 suggested desire disorders in 77.2%, arousal in 91.3%, lubrication in 96.6%, orgasm in 86.6%, satisfaction in 81.2% and pain in 64.4%. Age more than 40 and lower educational status were the contributory factors. In our study, we found orgasmic dysfunction (91.7% of patients) as the most common and desire dysfunction (48.2% of patients) as the least common. The association of FSD with advancing age can be the result of vaginal atrophy caused by peri-or postmenopausal estrogen deficit or it may confounded by complex cultural expectations and taboos that include women perception and expectations of the sexuality. The hypoestrogenic state of menopause may cause significant physical changes 6, 7 and alterations in mood or a diminished sense of well-being, which have been found to have a significant, negative impact on sexuality. Commercially available gels and creams are used for vaginal dryness and androgens are used to increase libido. Recently, sildenafil citrate has gained popularity to increase vaginal engorgement. HRT can be used in postmenopausal ladies to treat arousal and orgasmic disorders. The mechanism of estrogens effect on desire is indirect and occurs through improvement in urogenital atrophy, vasomotor symptoms and menopausal mood disorders (i.e. depression). Testosterone appears to have a direct role in sexual desire.
